Log in

DiaMedica Therapeutics Stock Forecast, Price & News

+0.17 (+3.05 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $5.75
50-Day Range
MA: $4.45
52-Week Range
Now: $5.75
Volume485,500 shs
Average Volume69,305 shs
Market Capitalization$107.76 million
P/E RatioN/A
Dividend YieldN/A
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:DMAC



Sales & Book Value

Annual Sales$500,000.00
Book Value$1.59 per share


Net Income$-10,650,000.00


Market Cap$107.76 million
Next Earnings Date3/22/2021 (Estimated)
OptionableNot Optionable
+0.17 (+3.05 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

How has DiaMedica Therapeutics' stock been impacted by Coronavirus?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DMAC shares have increased by 43.8% and is now trading at $5.75.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DiaMedica Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than DiaMedica Therapeutics?

Wall Street analysts have given DiaMedica Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DiaMedica Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 22nd 2021.
View our earnings forecast for DiaMedica Therapeutics

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Wednesday, November, 4th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.04.
View DiaMedica Therapeutics' earnings history

What price target have analysts set for DMAC?

4 brokers have issued 1-year target prices for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $16.00. On average, they expect DiaMedica Therapeutics' share price to reach $14.75 in the next year. This suggests a possible upside of 156.5% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a increase in short interest in October. As of October 30th, there was short interest totaling 32,000 shares, an increase of 33.3% from the October 15th total of 24,000 shares. Based on an average daily volume of 45,100 shares, the days-to-cover ratio is currently 0.7 days.
View DiaMedica Therapeutics' Short Interest

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Dietrich John Pauls M.B.A., MBA, Pres, CEO & Director (Age 49, Pay $612.65k)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 55, Pay $341.25k)
  • Dr. Harry W. Alcorn Jr., Chief Medical Officer (Age 64, Pay $356.55k)
  • Dr. Edward G. Calamai, Consulting Head of Manufacturing

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (6.12%), Point72 Asset Management L.P. (4.27%), Nantahala Capital Management LLC (4.04%), Corriente Advisors LLC (3.90%), Granite Point Capital Management L.P. (3.45%) and Manatuck Hill Partners LLC (3.05%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends for DiaMedica Therapeutics

Which institutional investors are buying DiaMedica Therapeutics stock?

DMAC stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Corriente Advisors LLC, Stonepine Capital Management LLC, Manatuck Hill Partners LLC, Granite Point Capital Management L.P., Boothbay Fund Management LLC, Worth Venture Partners LLC, and Nantahala Capital Management LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen.
View insider buying and selling activity for DiaMedica Therapeutics

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $5.75.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $107.76 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 8 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.